Paper II — 2023 March (Supplementary) (2010 Scheme) — Q4
2 min read
Paper II
2023 March (Supplementary) (2010 Scheme)
Question
Albendazole
Q43 marksShort Notes
Answer
Albendazole is a broad-spectrum benzimidazole anthelmintic.
MOA: albendazole → binds parasitic beta-tubulin → inhibits microtubule polymerization → the parasite cannot maintain its cytoskeleton, transport glucose across its gut lining, or divide → energy depletion and death over days. Selectivity relies on higher affinity for parasitic than mammalian beta-tubulin.
Adverse effects: GI upset, hepatotoxicity with prolonged/high-dose use, teratogenicity (avoided in pregnancy), bone marrow suppression with prolonged high-dose therapy (as in hydatid disease treatment).